The Role of Phosphodiesterases in Schizophrenia : Therapeutic ImplicationsSIUCIAK, Judith A.CNS drugs. 2008, Vol 22, Num 12, pp 983-993, issn 1172-7047, 11 p.Article

Phosphodiesterase Type 5 Inhibitor Use and Hearing ImpairmentMCGWIN, Gerald.Archives of otolaryngology, head & neck surgery. 2010, Vol 136, Num 5, pp 488-492, issn 0886-4470, 5 p.Article

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? CommentaryCROSBY, R; YARBER, W. L; SANDERS, S. A et al.Sexually transmitted infections. 2009, Vol 85, Num 5, pp 404-406, issn 1368-4973, 3 p.Article

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risksJACKSON, G; ARVER, S; BANKS, I et al.International journal of clinical practice (Esher). 2010, Vol 64, Num 4, pp 497-504, issn 1368-5031, 8 p.Article

Role of Growth Factors in Improved Skin Flap Viability Caused by Phosphodiesterase-5 InhibitorBANDERA, Bradley C; PHAM, Thach; HILL-PRYOR, Crystal et al.The American surgeon. 2010, Vol 76, Num 6, pp 614-617, issn 0003-1348, 4 p.Article

Transitiometric analysis of solid II/solid I transition in anhydrous theophyllineLEGENDRE, Bernard; RANDZIO, Stanislaw L.International journal of pharmaceutics. 2007, Vol 343, Num 1-2, pp 41-47, issn 0378-5173, 7 p.Article

Modulation of Morphine-induced Antinociception in Acute and Chronic Opioid Treatment by IbudilastLILIUS, Tuomas O; RAUHALA, Pekka V; KAMBUR, Oleg et al.Anesthesiology (Philadelphia). 2009, Vol 111, Num 6, pp 1356-1364, issn 0003-3022, 9 p.Article

Insuffisance érectile : Prescrire un inhibiteur de la phosphodiestérase 5 en première intentionSTAERMAN, Frédéric.Concours médical (Paris). 2009, Vol 131, Num 7, pp 221-224, issn 0010-5309, 4 p.Article

Pyrazoloquinolines as PDE10A inhibitors: Discovery of a tool compoundMCELROY, William T; ZHENG TAN; XIAOPING ZHANG et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 3, pp 1335-1339, issn 0960-894X, 5 p.Article

Intérêt thérapeutique d'un inhibiteur de la phosphodiestérase de type 5 et d'un antagoniste sélectif des récepteurs de l' endothéline AALLANORE, Yannick.La Revue de médecine interne (Paris). 2010, Vol 31, pp 8-9, issn 0248-8663, 2 p., HS1Article

Classification trees based on infrared spectroscopic data to discriminate between genuine and counterfeit medicinesDECONINCK, E; SACRE, P. Y; COOMANS, D et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 57, Num C, pp 68-75, issn 0731-7085, 8 p.Article

The Successful Use of Phosphodiesterase Type 5 Inhibitors to Treat the Syndrome of Cor Pulmonale and Prerenal Azotemia with Diuresis of Anasarca (CorPRADA)BEREZ, Paul Bruce.Southern medical journal (Birmingham, Ala. Print). 2010, Vol 103, Num 2, pp 116-120, issn 0038-4348, 5 p.Article

Effect of phosphodiesterase-5 inhibitor on hearingOKUYUCU, S; GUVEN, O. E; AKOGLU, E et al.Journal of laryngology and otology. 2009, Vol 123, Num 7, pp 718-722, issn 0022-2151, 5 p.Article

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysisTSERTSVADZE, Alexander; FINK, Howard A; FOX, Steven et al.Annals of internal medicine. 2009, Vol 151, Num 9, pp 650-661, issn 0003-4819, 12 p.Article

Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunctionSADOVSKY, R; BROCK, G. B; GUTKIN, S. W et al.International journal of clinical practice (Esher). 2009, Vol 63, Num 8, pp 1214-1230, issn 1368-5031, 17 p.Article

Recovery of respiratory activity after C2 hemisection (C2HS): Involvement of adenosinergic mechanismsNANTWI, Kwaku D.Respiratory physiology & neurobiology. 2009, Vol 169, Num 2, pp 102-114, issn 1569-9048, 13 p.Article

Theophylline formulation by supercritical antisolventsROY, Christelle; VEGA-GONZALEZ, Arlette; SUBRA-PATERNAULT, Pascale et al.International journal of pharmaceutics. 2007, Vol 343, Num 1-2, pp 79-89, issn 0378-5173, 11 p.Article

Theophylline improves esophageal chest pain- : A randomized, placebo-controlled studyRAO, Satish S. C; MUDIPALLI, Ranjit S; REMES-TROCHE, Jose M et al.The American journal of gastroenterology. 2007, Vol 102, Num 5, pp 930-938, issn 0002-9270, 9 p.Article

Phosphodiesterase 5 inhibitors : Drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles : Phosphodiesterase 5 inhibitors : pharmacology and therapeutic perspectivesSUPURAN, Claudiu T; MASTROLORENZO, Antonio; BARBARO, Giuseppe et al.Current pharmaceutical design. 2006, Vol 12, Num 27, pp 3459-3465, issn 1381-6128, 7 p.Article

Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red lightGOTO, Makiko; IKEYAMA, Kazuyuki; TSUTSUMI, Moe et al.Experimental dermatology. 2011, Vol 20, Num 7, pp 568-571, issn 0906-6705, 4 p.Article

Erectile Dysfunction and Cardiovascular Disease : Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both ConditionsNEHRA, Ajay.Mayo Clinic proceedings. 2009, Vol 84, Num 2, pp 139-148, issn 0025-6196, 10 p.Article

Enhancement of transdermal delivery of theophylline using microemulsion vehicleZHAO, X; LIU, J. P; ZHANG, X et al.International journal of pharmaceutics. 2006, Vol 327, Num 1-2, pp 58-64, issn 0378-5173, 7 p.Article

Effects of Andrographolide on the Pharmacokinetics of Aminophylline and Doxofylline in RatsLI, X. P; ZHANG, C. L; GAO, P et al.Drug research (Stuttgart. 2013. Print). 2013, Vol 63, Num 5, pp 258-262, issn 2194-9379, 5 p.Article

Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial HypertensionARCHER, Stephen L; MICHELAKIS, Evangelos D.The New England journal of medicine. 2009, Vol 361, Num 19, pp 1864-1871, issn 0028-4793, 8 p.Article

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in menSTIRBAN, Alin; TAMLER, Ronald; ANDREI VERESIU, Loan et al.Journal of men's health (Print). 2011, Vol 8, Num 2, pp 109-118, issn 1875-6867, 10 p.Article